Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202121 | 0.82 | SMPD1 (0.37) | — | |
| SCHEMBL21402220 | 0.76 | TSHR (0.31) | TSHR | |
| SCHEMBL7006858 | 0.71 | SMPD1 (0.41) | — | |
| SCHEMBL16204386 | 0.69 | TSHR (0.40) | TSHRACHE | |
| SCHEMBL787693 | 0.67 | — | — | |
| SCHEMBL5909137 | 0.66 | TSHR (0.38) | TSHR | |
| SCHEMBL787694 | 0.65 | — | — | |
| Bicarbonate SCHEMBL10931175 | 0.65 | TSHR (0.33) | TSHR | |
| SCHEMBL9729488 | 0.64 | SMPD1 (0.37) | — | |
| SCHEMBL10931174 | 0.64 | ALDH1A1 (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115888415-A | Preparation method of nanofiltration membrane and nanofiltration membrane prepared by same | 沃顿科技股份有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115888415-A | Preparation method of nanofiltration membrane and nanofiltration membrane prepared by same | 沃顿科技股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-8318933-B2 | Process for preparing rosuvastatin calcium | AUROBINDO PHARMA LTD (IN) | 2012-11-27 | — | — | US | disclosed |
| US-20100048899-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LTD (IN) | 2010-02-25 | — | — | US | disclosed |
| EP-2079712-A2 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008053334-A2 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-05-08 | — | — | WO | disclosed |
| EP-1057814-B1 | TETRAHYDROBENZINDOLE DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-6498251-B1 | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-6407112-B1 | 2A,3,4,5-TETRAHYDRO-1H-BENZ(CD)INDOL-2-ONE DERIVATIVES; 5-HYDROXYTRYPTAMINE AGONISTS; SLEEP, CIRCADIAN RHYTHYM, BIPOLAR, AND PSYCHOLOGICAL DISORDER TREATMENT | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1081136-A1 | OPTICALLY ACTIVE TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048899-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | CACNA1I, CACNA1S, CACNA1F | TSHR 4503/4885ACHE 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.